Ribomic Inc. | Balance Sheet

Fiscal year is April-March. All values JPY Millions.
2014
2015
2016
2017
2018
2019
Cash & Short Term Investments
331
3,337
3,060
2,384
2,181
2,414
Total Accounts Receivable
103
44
36
34
35
22
Inventories
6
1
5
7
14
8
Other Current Assets
4
5
11
9
11
57
Total Current Assets
443
3,387
3,113
2,433
2,240
2,502
Net Property, Plant & Equipment
35
20
54
48
46
26
Total Investments and Advances
13
11
15
12
38
23
Intangible Assets
-
-
-
-
-
2
Other Assets
1
1
2
2
3
16
Total Assets
493
3,420
3,183
2,496
2,327
2,569
Income Tax Payable
4
11
8
15
17
Other Current Liabilities
135
145
136
42
82
Total Current Liabilities
139
157
144
57
100
Total Liabilities
139
157
144
57
100
Common Equity (Total)
354
3,263
3,039
2,439
2,227
Total Shareholders' Equity
354
3,263
3,039
2,439
2,227
Total Equity
354
3,263
3,039
2,439
2,227
Liabilities & Shareholders' Equity
493
3,420
3,183
2,496
2,327

About Ribomic

View Profile
Address
Shirokanedai Usui Building, 6/F
Tokyo Tokyo 108
Japan
Employees -
Website http://www.ribomic.com/
Updated 07/08/2019
RIBOMIC, Inc. engages in the research and development of molecular targeted drugs using Ribonucleic Acid (RNA) aptamers for use in therapeutic fields. It utilizes RiboART system, a platform technology essentially applicable to any target proteins, and not limited to disease. The company was founded by Yoshikazu Nakamura on August 1, 2003 and is headquartered in Tokyo, Japan.